Another example, aprotinin, is a naturally-occurring broad-spectrum protease inhibitor; some countries refuse to approve this medication because it supposedly has a greater mortality rate than its alternatives (tranexamic acid and aminocaproic acid) and causes damage to the kidneys and heart.
Aprotinin, a naturally occurring broad-spectrum protease inhibitor, faces rejection in some countries due to concerns about its mortality rate compared to tranexamic acid and aminocaproic acid, as well as potential kidney and heart damage.